Albany Molecular Research's Indian r&d centre to open in 2007
Global drug discovery company, Albany Molecular Research (ABR), of New York, USA, says construction has started on its new 50,000 sq ft r&d centre at the Shapoorji Pallonji Biotech Park in Hyderabad, India. The build represents the first major expansion of the company's Hyderabad Research Centre, a subsidiary of ABR.
Global drug discovery company, Albany Molecular Research (ABR), of New York, USA, says construction has started on its new 50,000 sq ft r&d centre at the Shapoorji Pallonji Biotech Park in Hyderabad, India. The build represents the first major expansion of the company's Hyderabad Research Centre, a subsidiary of ABR.
When completed in late 2007, the new centre will conduct contract projects in early stage drug discovery research, including custom chemical synthesis and medicinal chemistry. In addition, the new facility will house a scale-up laboratory for developing new methods of producing larger quantities of active pharmaceutical ingredients and intermediates.
When fully staffed, the new facility will add over 100 employees to the company's existing Hyderabad operations, which currently have 19 employees in the nearby ICICI Knowledge Park. The current facility can accommodate up to 40 employees and is expected to reach full capacity in the coming months.
"The expansion of our Hyderabad Research Centre will enhance our ability to provide customers with a range of flexible drug discovery and development services and cost options," said AMRI chairman, ceo and president Thomas D'Ambra.